This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n6http://www.drugs.com/
n18http://www.rxlist.com/
n15http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB08935/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08935
rdf:type
n3:Drug
n3:description
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
n3:dosage
n4:271B5E0D-363D-11E5-9242-09173F13E4C5 n4:271B5E0E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# FDA label.
n3:group
approved
n3:halfLife
The half life of obinutuzumab is 28.4 days.
n3:indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
owl:sameAs
n15:DB08935
dcterms:title
Obinutuzumab
adms:identifier
n9:D09321 n10:50242-070-01 n13:DB08935 n16:Obinutuzumab
n3:mechanismOfAction
In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
n3:routeOfElimination
The route of elimination of obinutuzumab was not indicated (FDA label).
n3:synonym
Afutuzumab
n3:toxicity
The most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.
n3:volumeOfDistribution
Obinutuzumab has a volume of distribution of about 3.8 L.
n3:foodInteraction
Echinacea: diminished therapeutic effect of immunosuppressants
n3:proteinBinding
Obinutuzumab does not bind to plasma proteins.
n3:synthesisReference
Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96.
foaf:page
n6:gazyva.html n18:gazyva-drug.htm
n3:Molecular-Formula
n7:271B5E11-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B5E10-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B5E0F-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:L01XC15
n3:absorption
Obinutuzumab is administered intravenously, so its absorption is 100%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
949142-50-1
n3:category
n3:clearance
The clearance of obinutuzumab is 0.09L/day.